Login to Your Account



Tyg, Oncoqr design new rocket to power pancreatic cancer 'warhead'

By Marie Powers
News Editor

Friday, March 11, 2016

Tyg Oncology Ltd. and Oncoqr ML GmbH are relative newcomers to the field of cancer immunotherapy but their platforms are not. What's different now is that Tyg's lead vaccine candidate, TYG100, is powered by the S-TIR technology platform.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription